| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -2.8 | -1.0 |
| EPS (diluted, $ a share) | $-1.86 | $-0.75 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CURX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Curanex Pharmaceuticals Inc: key numbers
- Share price
- $4.70Close, Nov 17
- Market cap
- $7.37M
- Shares outstanding
- 1.57MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Curanex Pharmaceuticals Inc
All →Curanex Pharmaceuticals Court & Legal Update
Curanex Pharmaceuticals disclosed two putative securities class action lawsuits filed in the Supreme Court of the State of New York related to its August 2025 IPO. The complaints allege material misstatements and omissions in the IPO offering documents regarding risks of stock-price manipulation and underwriter due diligence deficiencies. The company intends to defend the actions vigorously and has received extensions to respond to the complaints through late 2026.
- Counterparty
- Daymond Morales and Robert Lovett